{"id":"amisulpride-iv","safety":{"commonSideEffects":[{"rate":"10%","effect":"Akathisia"},{"rate":"5%","effect":"Dyskinesia"},{"rate":"20%","effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL243712","moleculeType":"Small molecule","molecularWeight":"369.49"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Amisulpride acts as a selective antagonist of dopamine D2 and D3 receptors, which are involved in the regulation of motor function and the modulation of the dopaminergic system.","oneSentence":"Dopamine D2/D3 receptor antagonist","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:54:16.597Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"}]},"trialDetails":[{"nctId":"NCT07348172","phase":"EARLY_PHASE1","title":"Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-03-01","conditions":"Drug Liking","enrollment":100},{"nctId":"NCT05546359","phase":"PHASE2, PHASE3","title":"Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2024-01-18","conditions":"Nausea and Vomiting, Postoperative","enrollment":453},{"nctId":"NCT06887621","phase":"PHASE2","title":"Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery","status":"RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2025-04-10","conditions":"Post Operative Nausea and Vomiting (PONV)","enrollment":276},{"nctId":"NCT06585540","phase":"PHASE3","title":"A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population","status":"RECRUITING","sponsor":"Benaroya Research Institute","startDate":"2024-09-13","conditions":"Post Operative Nausea and Vomiting","enrollment":100},{"nctId":"NCT05822713","phase":"PHASE3","title":"A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical (Hainan) Co., Ltd.","startDate":"2023-04-29","conditions":"PONV","enrollment":516},{"nctId":"NCT04954365","phase":"","title":"Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment","status":"WITHDRAWN","sponsor":"Acacia Pharma Ltd","startDate":"2022-11-01","conditions":"Nausea and Vomiting, Postoperative","enrollment":""},{"nctId":"NCT04849650","phase":"PHASE1","title":"PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2021-06-03","conditions":"Renal Disease, End Stage","enrollment":12},{"nctId":"NCT01857232","phase":"PHASE2","title":"Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2013-10","conditions":"CINV","enrollment":342},{"nctId":"NCT01991821","phase":"PHASE3","title":"European Phase III Study of APD421 in PONV","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2013-07","conditions":"PONV","enrollment":368},{"nctId":"NCT02337062","phase":"PHASE3","title":"Phase IIIb Study of APD421 in Combination as PONV Prophylaxis","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2015-02","conditions":"PONV","enrollment":1147},{"nctId":"NCT01991860","phase":"PHASE3","title":"US Phase III Study of APD421 in PONV","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2013-08","conditions":"PONV","enrollment":364},{"nctId":"NCT02646566","phase":"PHASE3","title":"Study of APD421 as PONV Treatment (Prior Prophylaxis)","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2016-03","conditions":"Postoperative Nausea and Vomiting","enrollment":705},{"nctId":"NCT02449291","phase":"PHASE3","title":"Study of APD421 as PONV Treatment (no Prior Prophylaxis)","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2015-09","conditions":"Postoperative Nausea and Vomiting","enrollment":568}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":56,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Amisulpride IV","genericName":"Amisulpride IV","companyName":"Acacia Pharma Ltd","companyId":"acacia-pharma-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dopamine D2/D3 receptor antagonist Used for Schizophrenia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}